Lead
When influenza hits, antiviral medicines can shorten illness and cut transmission. In the United States the CDC currently recommends four antivirals: oseltamivir (Tamiflu), baloxavir (Xofluza), zanamivir (Relenza) and peramivir (Rapivab). Each drug has distinct age approvals, routes of administration, typical costs and side‑effect profiles, so the best choice depends on patient age, setting and medical history. Antivirals are most effective when started within 48 hours of symptom onset.
Key takeaways
- The CDC lists four recommended flu antivirals: oseltamivir, baloxavir, zanamivir and peramivir.
- Tamiflu (oseltamivir) is approved for treatment in people 2 weeks and older and for prevention in those 1 year and older; typical outpatient treatment is twice daily for five days; retail cost without insurance is about $50 or less.
- Xofluza (baloxavir) is a single‑dose oral tablet approved for ages 5 and up; retail cost can be about $200 without insurance but coupons often reduce out‑of‑pocket price.
- Relenza (zanamivir) is an inhaled powder for ages 7 and older to treat (preventive use from age 5); it’s given twice daily for five days and is not recommended for people with breathing disorders.
- Rapivab (peramivir) is an intravenous single infusion for ages 6 months and older, typically administered in a clinic or hospital; retail cost can approach $1,000 without coverage.
- A 2023 study cited by clinicians noted roughly 18% vomiting with oseltamivir versus about 5% with baloxavir, while baloxavir has been associated with diarrhea in around 5% of patients.
- Baloxavir can halt viral shedding more quickly than oseltamivir—often within a day—potentially lowering household exposure, but emergence of resistance during treatment has been observed.
Background
Seasonal influenza causes annual surges in outpatient visits and hospitalizations, and antivirals are a core tool both to reduce symptom duration and to prevent severe outcomes in vulnerable patients. For decades oseltamivir was the dominant outpatient antiviral; newer options such as baloxavir (approved in recent years) expanded choices for clinicians and patients. Regulatory approvals define age groups and routes of administration; those limits, plus safety data, shape which drug is appropriate for each patient.
Availability, cost and insurance coverage have also influenced prescribing patterns. Oral oseltamivir became widely used because it is available in generic form and familiar to prescribers; baloxavir’s one‑dose convenience and improving coverage have raised demand, though supply can vary by region and pharmacy. For hospitalized or critically ill patients, intravenous options and evidence from clinical trials guide practice differently than for otherwise healthy outpatients.
Main event
Oseltamivir (generic Tamiflu) remains the most commonly prescribed antiviral for many patients. The drug is authorized for treatment in infants aged 2 weeks and older and for prophylaxis in people 1 year and older. Standard treatment is twice daily for five days; for post‑exposure prevention it is usually given once daily for 10 days. Clinicians report nausea and vomiting as the most frequent adverse effects.
Baloxavir (Xofluza) is taken as a single oral dose and is approved for people aged 5 and older for both treatment and prevention. The single‑dose regimen is a strong convenience advantage for many outpatients and families. Without insurance the retail price can be near $200, though manufacturer coupons and insurer formularies may lower patient cost. Reported common side effects include diarrhea and occasional vomiting.
Peramivir (Rapivab) is a single intravenous infusion given by a health care professional and is approved for patients 6 months and older. It is most often used in settings where oral or inhaled therapy is not suitable. Because it requires infusion it is typically more expensive in the outpatient retail sense—costs may approach $1,000 without insurance—and clinicians note diarrhea as a common adult adverse reaction.
Zanamivir (Relenza) is an inhaled powder administered twice daily for five days using a dedicated inhaler device. The drug is approved for treatment in people 7 and older and for prevention in those 5 and older. Typical retail cost may be up to about $90 without insurance. Relenza can cause bronchospasm or breathing symptoms and is therefore not recommended for patients with asthma or other significant respiratory disease.
Analysis & implications
The practical differences among these antivirals affect individual and public‑health decisions. A single dose of baloxavir simplifies adherence and may rapidly reduce viral shedding, which could lower household transmission; however, emergence of resistance during or after baloxavir treatment has been observed and is a clinical concern. Oseltamivir’s longer dosing course remains a reliable option, particularly where resistance risk or limited safety data make providers cautious.
Access and cost are central. While generic oseltamivir is relatively inexpensive, baloxavir’s higher retail price has been mitigated in many cases by coupons and broader insurance coverage, increasing its uptake. Nonetheless, regional pharmacy stock, insurer formularies and prescriber familiarity continue to shape which antivirals patients actually receive during a given influenza season.
For hospitalized patients and people with progressive or severe illness, public‑health guidance currently favors oseltamivir because it has more evidence and experience in those settings. Experts are calling for additional studies of combination therapy—oseltamivir plus baloxavir or other agents—for severe influenza to determine whether combined antivirals improve outcomes.
Comparison & data
| Drug | Generic | Age approval | Route / dosing | Typical retail cost (no insurance) | Common side effects |
|---|---|---|---|---|---|
| Tamiflu | Oseltamivir | Treatment: ≥2 weeks; Prevention: ≥1 year | Oral; twice daily ×5 days (treatment) | ≈$50 or less | Nausea, vomiting |
| Xofluza | Baloxavir | ≥5 years | Oral; single dose | ≈$200 (coupons often reduce cost) | Diarrhea, vomiting |
| Relenza | Zanamivir | Treat ≥7 years; Prevent ≥5 years | Inhaled powder; twice daily ×5 days | ≈$90 | Allergic reaction, nasal irritation, dizziness; bronchospasm risk |
| Rapivab | Peramivir | ≥6 months | IV infusion; single dose | Up to ≈$1,000 | Diarrhea |
The table highlights tradeoffs: route (oral vs inhaled vs IV), dosing convenience, age limits and cost. These factors, together with patient comorbidities and local availability, determine which antiviral is optimal for an individual.
Reactions & quotes
Clinicians and national experts emphasize real‑world tolerability and resistance considerations when choosing treatment.
I hear the most complaints about vomiting from Tamiflu, and a 2023 study showed about 18% of people experienced vomiting with oseltamivir versus roughly 5% with baloxavir.
Dr. Ari Brown, pediatrician
Practitioners note resistance with baloxavir may influence prescribing.
The influenza virus can develop resistance to baloxavir during treatment in about 10% of cases, so that has tempered broader use.
Dr. William Schaffner, infectious disease expert, Vanderbilt University Medical Center
Federal public‑health officials weigh risks and benefits across patient groups.
Baloxavir resistance has appeared more frequently in younger children and is associated with longer symptoms, yet person‑to‑person spread of resistant virus remains very uncommon.
Dr. Tim Uyeki, CDC National Center for Immunization and Respiratory Diseases (COCA call)
Unconfirmed
- Regional shortages of Xofluza are reported anecdotally and by some clinicians, but comprehensive national shortage data were not provided in the sources cited.
- The precise frequency of baloxavir resistance in different age groups varies by study; statements about rates in children are based on emerging data and surveillance rather than uniform national estimates.
Bottom line
Four antiviral options are recommended by the CDC for outpatient influenza treatment in the US, and each has specific age approvals, administration routes and side‑effect profiles. Tamiflu remains the most commonly used due to wide availability, low cost and familiarity, while Xofluza’s single‑dose regimen offers important advantages for adherence and rapid reduction in viral shedding.
Clinicians must weigh convenience, safety data, pregnancy and immunosuppression exclusions, resistance risk and local availability when choosing therapy. For severe or hospitalized influenza, oseltamivir remains preferred pending more data on combination regimens and on baloxavir’s role in those settings.